胸腺上皮瘤（TET），包括胸腺瘤和胸腺癌和胸腺神经内分泌肿瘤，是一种与发病率和死亡率相关的恶性肿瘤。最近，世界卫生组织（WHO）胸部肿瘤第5版分类学于2021年发布了更新的版本，其中对这些肿瘤的分类进行了各种改变。此外，2017年国际癌症联合会（UICC）/美国肿瘤学委员会（AJCC）发布了第8版分期手册，首次包括适用于胸腺瘤、胸腺癌和胸腺神经内分泌肿瘤的TNM分期。为规范对切除的TET和胸腺神经内分泌肿瘤的报告，认证机构更新了其报告规程。国际癌症报告协作组织（ICCR），代表了各国病理学协会之间的合作，相应地更新了其2017年关于TET和胸腺神经内分泌肿瘤的组织病理学报告指南。本报告将强调基于2021年WHO的TET和胸腺神经内分泌肿瘤报告中的重要变化，强调2017年TNM分期，并对病理学家在遵循该分期时的严谨度和各种不确定性发表评论。ICCR数据集提供了对切除的TET和胸腺神经内分泌肿瘤进行报告的全面、标准化的模板。© 2023 John Wiley & Sons Ltd.

Thymic epithelial tumours (TET), including thymomas and thymic carcinomas and thymic neuroendocrine neoplasms, are malignant neoplasms that can be associated with morbidity and mortality. Recently, an updated version of the World Health Organization (WHO) Classification of Thoracic Tumours 5th Edition, 2021 has been released, which included various changes to the classification of these neoplasms. In addition, in 2017 the Union for International Cancer Control (UICC) / American Joint Committee on Cancer (AJCC) published the 8th Edition Staging Manual which, for the first time, includes a TNM staging that is applicable to thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms.To standardize reporting of resected TET and thymic neuroendocrine neoplasms the accrediting bodies updated their reporting protocols. The International Collaboration on Cancer Reporting (ICCR), which represents a collaboration between various National Associations of Pathology, updated its 2017 histopathology reporting guide on TET and thymic neuroendocrine neoplasms accordingly. This report will highlight important changes in the reporting of TET and thymic neuroendocrine neoplasms based on the 2021 WHO, emphasize the 2017 TNM staging, and also comment on the rigour and various uncertainties for the pathologist when trying to follow that staging.The ICCR dataset provides a comprehensive, standardized template for reporting of resected TET and thymic neuroendocrine neoplasms.© 2023 John Wiley & Sons Ltd.